Last reviewed · How we verify
LEXIVA (GW433908)
Lexiva is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and inhibiting viral replication.
Lexiva is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and inhibiting viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients (in combination with other antiretroviral agents).
At a glance
| Generic name | LEXIVA (GW433908) |
|---|---|
| Sponsor | ViiV Healthcare |
| Drug class | HIV protease inhibitor |
| Target | HIV-1 protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Lexiva (fosamprenavir) is a prodrug that is rapidly converted to amprenavir in vivo. It inhibits HIV-1 protease, an enzyme essential for processing viral proteins during HIV replication. By preventing protease-mediated cleavage of viral polyproteins, the drug produces immature, non-infectious viral particles and suppresses HIV replication.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients (in combination with other antiretroviral agents)
Common side effects
- Diarrhea
- Nausea
- Rash
- Headache
- Vomiting
- Elevated transaminases
Key clinical trials
- Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction (PHASE2)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Oral Fosamprenavir + Sodium Alginate for GERD (PHASE2)
- Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects (PHASE2)
- Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People (NA)
- Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEXIVA (GW433908) CI brief — competitive landscape report
- LEXIVA (GW433908) updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI